Scott Henry

- Palatin Technologies, Inc. announced the achievement of a research milestone in its collaboration with Boehringer Ingelheim, resulting in a **€5.5 million ($6.5 million)** payment.  **[911216_0001654954-25-010973_ptn_ex991.htm:0]** **[911216_0001654954-25-010973_ptn_8k.htm:1]** 
- This collaboration, established on **August 18, 2025**, aims to develop melanocortin receptor-targeted treatments for **diabetic retinopathy and diabetic macular edema**.  **[911216_0001654954-25-010973_ptn_ex991.htm:0]** 
- Under the agreement, Palatin received an **upfront payment of €2.0 million ($2.3 million)** and is eligible for up to **€18.0 million ($21.2 million)** in near-term research milestones (including the current payment), and up to **€260 million ($307 million)** in success-based development, regulatory, and commercial milestone payments, plus tiered royalties on net sales.  **[911216_0001654954-25-010973_ptn_ex991.htm:0]** **[911216_0001654954-25-010973_ptn_8k.htm:1]**

Palatin Technologies Announces Milestone Payment from Boehringer Ingelheim Collaboration

- Palatin Technologies (PTNT) announced on **September 22, 2025**, the achievement of a research milestone under its collaboration with Boehringer Ingelheim.  **[911216_20250922PH78057:0]** 
- This milestone triggered a payment of **€5.5 million ($6.5 million)** to Palatin.  **[911216_20250922PH78057:0]** 
- The collaboration, which began on **August 18, 2025**, is focused on developing potential first-in-class melanocortin receptor-targeted treatments for patients with diabetic retinopathy, including diabetic macular edema.  **[911216_20250922PH78057:0]** 
- Palatin is eligible for additional research, development, regulatory, and commercial milestone payments of up to **€278 million ($328 million)**, as well as tiered royalties on net sales from this partnership.  **[911216_20250922PH78057:0]**

PALATIN TECHNOLOGIES (PTNT)